The latest financial statement is for the year ending 2025-12-31.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -16,210,718 |
| Share based compensation | 1,202,954 |
| Stock option expense (note 2) | 1,472,279 |
| Depreciation and amortization | 615,720 |
| Impairment loss | 2,640,280 |
| Inventory write down | 312,151 |
| Accretion expense | 202,801 |
| Change in fair value of convertible debt | 21,000 |
| (gain) loss on sale and disposal of assets | -163,248 |
| Non-cash lease expense | 277,036 |
| Accounts and other receivable, net | -114,630 |
| Accounts receivable - related party | 43,792 |
| Inventories | 99,561 |
| Prepaid expenses and other assets | -791,288 |
| Accounts payable and accrued liabilities (note 2) | -2,073,730 |
| Accounts payable and accrued expense - related party | 3,557 |
| Operating lease liabilities | -326,730 |
| Net cash used in operating activities | -10,979,587 |
| Payment for intangible asset | 700,000 |
| Payment for intangible asset-related party | 350,000 |
| Purchase of property and equipment | 1,216 |
| Proceeds from sales of property and equipment | 17,815 |
| Net cash used in investing activities | -1,033,401 |
| Sale of ordinary shares, pre-funded warrants, and warrants | 8,248,261 |
| Repayments of convertible debt | 1,000,000 |
| Payments on silent partnerships | 243,405 |
| Payments on loan payable | 241,816 |
| Net cash provided by financing activities | 6,763,040 |
| Effect of changes in exchange rates | -96,631 |
| Net change in cash | -5,346,579 |
| Cash at beginning of year | 6,235,670 |
| Cash at end of year | 889,091 |
MAINZ BIOMED N.V. (MYNZ)
MAINZ BIOMED N.V. (MYNZ)